参考文献/References:
[1]Seikrit C,Rauen T,Floege J.Immunglobulin-A-Nephropathie [Immunoglobulin A nephropathy][J].Internist (Berl),2019,60(5):432-439.[2]Yi J,He Z,Xu S,et al.Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis[J].Int Urol Nephrol,2019,51(11):1987-1998.[3]Tsunoda R,Usui J,Hoshino J,et al.Corticosteroids pulse therapy and oral corticosteroids therapy for IgA nephropathy patients with advanced chronic kidney disease: results of a multicenter, large-scale, long-term observational cohort study[J].BMC Nephrol,2018,19(1):222.[4]Katafuchi R,Ninomiya T,Mizumasa T,et al.The improvement of renal survival with steroid pulse therapy in IgA nephropathy[J].Nephrol Dial Transplant,2008,23(12):3915-3920.[5]Wu H,Fang X,Xia Z,et al.Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children-a retrospective 1243 cases analysis from single centre experience[J].J Nephrol,2020,33(6):1263-1273.[6]贾卿.免疫抑制剂治疗IgA肾病CKD3-4期患者的有效性及安全性研究[D].西安:空军军医大学,2022.[7]Rauen T,Fitzner C,Eitner F,et al.Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy[J].J Am Soc Nephrol,2018,29(1):317-325.[8]Beck N,Walz G,Schneider J.Effect of Cyclophosphamide and Glucocorticoid Therapy in IgA Nephropathy: A Single-Center Retrospective Analysis[J].Kidney360,2022,3(3):506-515.[9]李婉,李琴.强的松联合环磷酰胺治疗增生硬化性IgA肾病疗效及对血肌酐和蛋白尿水平的影响[J].实用医院临床杂志,2021,18(4):99-102.[10]韩亚男.他克莫司联合糖皮质激素治疗儿童原发性IgA肾病的疗效及安全性评价[D].石家庄:河北医科大学,2021.[11]李英楠,安自民.贝那普利联合硫唑嘌呤治疗中等量蛋白尿IgA肾病的疗效分析[J].华北煤炭医学院学报,2011,13(4):471-472.[12]沈世忠,杨忠民,蔡佳盈,等.来氟米特与泼尼松对免疫球蛋白A肾病的临床疗效与安全性研究[J].中国临床药理学杂志,2016,32(1):6-8.[13]杨莉萌,梁燕.糖皮质激素联合来氟米特对IgA肾病患者TLR-9、VCAM-1水平的影响[J].医学理论与实践,2021,34(10):1689-1691.[14]Du B,Jia Y,Zhou W,et al.Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis[J].BMC Nephrol,2017,18(1):245.[15]Liu X,Dewei D,Sun S,et al.Treatment of severe IgA nephropathy: mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone[J].Int J Clin Pharmacol Ther,2014,52(2):95-102.[16]Hou JH,Le WB,Chen N,et al.Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial[J].Am J Kidney Dis,2017,69(6):788-795.[17]张沛,周昱,高春林,等.咪唑立宾联合糖皮质激素治疗儿童IgA肾病的临床研究[J].东南国防医药,2022,24(4):356-361.[18]Xie Y,Huang S,Wang L,et al.Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study[J].Am J Med Sci,2011,341(5):367-372.[19]沈炎.他克莫司治疗原发性IgA肾病伴轻中度肾功能损伤的随机对照临床研究[J].中西医结合心血管病电子杂志,2017,5(22):187.[20]Kim YC,Chin HJ,Koo HS,et al.Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure:a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy[J].PLoS One,2013,8(8):e71545.[21]包红梅,郭文岗,任稹,等.他克莫司联合激素治疗原发性IgA肾病伴轻中度肾功能损伤的疗效观察[J].医学综述,2016,22(14):2884-2887.[22]Xu L,Liu ZC,Guan GJ,et al.Cyclosporine A combined with medium/low dose prednisone in progressive IgA nephropathy[J].Kaohsiung J Med Sci,2014,30(8):390-395.[23]田燕,曾春兰.环孢霉素A与环磷酰胺联合激素对重症IgA肾病的疗效比较[J].中外医学研究,2021,19(18):143-145.[24]李俊杰,张勇.环孢霉素A与环磷酰胺联合激素对重症IgA肾病的疗效比较[J].河南医学研究,2018,27(18):3328-3330.[25]于国俊,罗方,程新，等.免疫抑制作用下雷公藤藤多甙片治疗IgA肾病效果观察[J].世界中医药,2018,13(11):2781-2784.[26]Chen N,Huang HL,Yang YD.Long-term effects of immunosuppression treatment on IgA nephropathy: a systematic review and meta-analysis[J].Ann Palliat Med,2021,10(11):11830-11839.[27]Ballardie FW,Roberts ISD.Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy[J].J Am Soc Nephrol,2002,13(1):142-148.[28]Hidaka Y,Tamura H,Furuie K,et al.Cyclosporine therapy could be considered for membranoproliferative glomerulonephritis with immunoglobulin A deposits: a case report[J].BMC Nephrol,2022,23(1):358.[29]Lv J,Wong MG,Hladunewich MA,et al.Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial[J].JAMA,2022,327(19):1888-1898.[30]Robert T,Cambier A,Hertig A.Intensive Supportive Care plus Immunosuppression in IgA Nephropathy[J].N Engl J Med,2016,374(10):991.[31]Rauen T,Wied S,Fitzner C,et al.After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy[J].Kidney Int,2020,98(4):1044-1052.[32]Pattrapornpisut P,Avila-Casado C,Reich HN.IgA Nephropathy: Core Curriculum 2021[J].Am J Kidney Dis,2021,78(3):429-441.[33]Zhang YM,Zhou XJ,Zhang H.What Genetics Tells Us About the Pathogenesis of IgA Nephropathy: The Role of Immune Factors and Infection[J].Kidney Int Rep,2017,2(3):318-331.[34]Beckwith H,Medjeral-Thomas N,Galliford J,et al.Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment[J].Nephrol Dial Transplant,2017,32(suppl_1):i123-i128.[35]Lv J,Liu L,Hao C,et al.Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria[J].Kidney Int Rep,2022,8(3):499-506.
相似文献/References:
[1]刘 枫.IgA肾病与系膜增生性肾炎临床特征的比较[J].医学信息,2019,32(16):95.[doi:10.3969/j.issn.1006-1959.2019.16.029]
LIU Feng.Comparison of Clinical Features between IgA Nephropathy and Mesangial Proliferative Nephritis[J].Journal of Medical Information,2019,32(14):95.[doi:10.3969/j.issn.1006-1959.2019.16.029]
[2]黄 婷,张亚莉,李 燕,等.不同性别IgA肾病患者相关临床指标及病理特点对比[J].医学信息,2019,32(21):125.[doi:10.3969/j.issn.1006-1959.2019.21.040]
HUANG Ting,ZHANG Ya-li,LI Yan,et al.Comparative Analysis of Clinical and Pathological Features of Patients with Different Sex IgA Nephropathy[J].Journal of Medical Information,2019,32(14):125.[doi:10.3969/j.issn.1006-1959.2019.21.040]
[3]陈钰泱,石爱杰.缬沙坦联合前列地尔治疗慢性肾小球肾炎的效果[J].医学信息,2020,33(15):151.[doi:10.3969/j.issn.1006-1959.2020.15.048]
CHEN Yu-yang,SHI Ai-jie.The Effect of Valsartan Combined with Alprostadil on Chronic Glomerulonephritis[J].Journal of Medical Information,2020,33(14):151.[doi:10.3969/j.issn.1006-1959.2020.15.048]
[4]刘永芳,王 莹.付义主任治疗IgA肾病经验[J].医学信息,2020,33(21):155.[doi:10.3969/j.issn.1006-1959.2020.21.048]
[5]陈 越,彭 莉.黄芪对细胞毒素相关蛋白A诱导的大鼠系膜细胞外基质分泌的影响[J].医学信息,2022,35(15):104.[doi:10.3969/j.issn.1006-1959.2022.15.023]
CHEN Yue,PENG Li.Effect of Astragalus Membranaceus on CagA-induced Extracellular Matrix Secretion of Rat Mesangial Cells[J].Journal of Medical Information,2022,35(14):104.[doi:10.3969/j.issn.1006-1959.2022.15.023]
[6]袁茜宁,董怡晨,卿玲玲,等.不同蛋白尿水平IgA肾病患者的临床及病理特征分析[J].医学信息,2024,37(08):104.[doi:10.3969/j.issn.1006-1959.2024.08.020]
YUAN Qian-ning,DONG Yi-chen,QING Ling-ling,et al.Analysis of Clinical and Pathological Characteristics of IgA Nephropathy Patients with Different Proteinuria Levels[J].Journal of Medical Information,2024,37(14):104.[doi:10.3969/j.issn.1006-1959.2024.08.020]